BioMarin Pharmaceutical Inc. (BMRN)
| Market Cap | 11.59B +2.8% |
| Revenue (ttm) | 3.24B +9.9% |
| Net Income | 268.74M -48.7% |
| EPS | 1.40 -48.4% |
| Shares Out | 193.28M |
| PE Ratio | 42.97 |
| Forward PE | 10.69 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 576,159 |
| Open | 60.43 |
| Previous Close | 60.02 |
| Day's Range | 59.85 - 60.69 |
| 52-Week Range | 49.26 - 66.28 |
| Beta | 0.24 |
| Analysts | Buy |
| Price Target | 87.92 (+46.63%) |
| Earnings Date | Aug 6, 2026 |
About BMRN
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company’s products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NA... [Read more]
Financial Performance
In 2025, BioMarin Pharmaceutical's revenue was $3.22 billion, an increase of 12.87% compared to the previous year's $2.85 billion. Earnings were $348.90 million, a decrease of -18.26%.
Financial StatementsAnalyst Summary
According to 25 analysts, the average rating for BMRN stock is "Buy." The 12-month stock price target is $87.92, which is an increase of 46.63% from the latest price.
News
Spruce Biosciences appoints Jessica Cohen Pfeffer as VP, clinical development
Spruce Biosciences (SPRB) announced the appointment of Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development. Cohen Pfeffer joins Spruce from BioMarin Pharmaceutical (BMRN), where she s...
BioMarin to Host Second Quarter 2026 Financial Results Conference Call and Webcast on Thursday, August 6, 2026, at 4:30pm ET
SAN RAFAEL, Calif., July 30, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a confe...
BioMarin and n-Lorem Foundation enter research collaboration in ReNU syndrome
BioMarin (BMRN) and n-Lorem Foundation, a nonprofit organization, announced a strategic collaboration and global exclusive license agreement to develop a first-in-disease, antisense oligonucleotide me...
BioMarin and n-Lorem Foundation Enter Early Research Collaboration to Develop Potential First-in-Disease Medicine for Newly Identified ReNU Syndrome
ReNU syndrome was discovered in 2024 and there are no medicines approved for the condition Collaboration combines BioMarin's leadership in genetic medicines with n-Lorem's pioneering antisense experti...
BioMarin price target raised to $76 from $75 at Citi
Citi analyst Eric Joseph raised the firm’s price target on BioMarin (BMRN) to $76 from $75 and keeps a Buy rating on the shares. The firm adjusted models in the…
BioMarin announces FDA accepts sNDA for full approval of Voxzogo
BioMarin (BMRN) Pharmaceutical announced that the U.S. FDA has accepted the company’s supplemental New Drug Application for Voxzogo for full approval in children with achondroplasia. The FDA has set a...
U.S. Food and Drug Administration Accepts BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO® (vosoritide) for Children With Achondroplasia
Application based on long-term safety and efficacy data from three ongoing studies, including adult height and additional clinical outcomes beyond linear growth, including body proportionality and arm...
BioMarin price target lowered to $62 from $66 at RBC Capital
RBC Capital analyst Luca Issi lowered the firm’s price target on BioMarin (BMRN) to $62 from $66 and keeps a Sector Perform rating on the shares as part of a…
BioMarin’s Voxzogo and BMN 333 show impact in hypochondroplasia, achondroplasia
BioMarin (BMRN) Pharmaceutical announced new data from studies of Voxzogo – vosoritide – in children with hypochondroplasia and the investigational medicine BMN 333 in achondroplasia presented at the ...
BioMarin Announces New Three-Year VOXZOGO® (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026
Data from an investigator-led study showed treatment with VOXZOGO resulted in sustained improvements in growth over three years in children with hypochondroplasia New Phase 1 results also presented fo...
Ascendis Pharma ‘oversold’ following ITC development, says Oppenheimer
Oppenheimer believes Ascendis Pharma (ASND) is oversold following a development in the ongoing ITC investigation into Yuviwel initiated by BioMarin (BMRN). Should the recommendation in a recent ITC st...
BioMarin Pharmaceutical Transcript: AGM 2026
The meeting established a quorum and proceeded with four proposals, including director elections, auditor ratification, executive compensation, and an equity plan amendment. All proposals passed by majority vote, with final results to be published in a Form 8-K.
3 Best Stocks to Buy This Week, According to Analysts – May 25-May 29
With markets calming after a busy earnings season, analysts pointed to three stocks stand out this week: Futu Holdings ($FUTU), Intuit ($INTU), and BioMarin Pharmaceutical ($BMRN). Analysts believe al...
BioMarin price target lowered to $111 from $116 at Canaccord
Canaccord lowered the firm’s price target on BioMarin (BMRN) to $111 from $116 and keeps a Buy rating on the shares. The firm updated its model following the news the…
BioMarin's drug shows significant growth gains in children in late-stage trial
BioMarin Pharmaceutical said on Wednesday its treatment for a rare condition that leads to short stature helped boost growth in children, meeting the main goal of a late-stage study and sending shar...
BioMarin’s Voxzogo meets endpoint in Phase 3 pediatric hypochondroplasia trial
BioMarin (BMRN) Pharmaceutical announced that the Phase 3 CANOPY-HCH-3 study evaluating treatment with Voxzogo – vosoritide – in children with hypochondroplasia met its primary endpoint, demonstrating...
BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO® (vosoritide) in Children with Hypochondroplasia
Study met primary endpoint, exceeding expectations with a highly statistically significant improvement in annualized growth velocity (AGV, change from baseline) of 2.33 cm/yr compared to placebo at we...
BioMarin price target lowered to $80 from $85 at BofA
BofA analyst Jason Zemansky lowered the firm’s price target on BioMarin (BMRN) to $80 from $85 and keeps a Buy rating on the shares after the company announced the Phase…
BioMarin initiated with a Buy at Citi
Citi initiated coverage of BioMarin (BMRN) with a Buy rating and $75 price target The firm views the stock’s “dislocated” valuation as a product of “overly cautious” views on Voxzogo’s…
BioMarin price target lowered to $62 from $64 at Leerink
Leerink lowered the firm’s price target on BioMarin (BMRN) to $62 from $64 and keeps a Market Perform rating on the shares after the company provided an update on the…
BioMarin price target lowered to $50 from $55 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on BioMarin (BMRN) to $50 from $55 and keeps a Neutral rating on the shares. The company’s Phase 3 ENERGY 3 study in…
BioMarin's genetic disease therapy shows mixed results in late-stage study
BioMarin Pharmaceutical said on Monday its experimental treatment for a rare genetic condition met one of the two main goals in a late-stage study.
BioMarin’s BMN 401 meets 1 of 2 endpoints in Phase 3 ENPP1 trial
BioMarin (BMRN) announced results from the pivotal Phase 3 ENERGY 3 trial evaluating BMN 401 in children aged 1-12 with ENPP1 deficiency, a rare, serious and progressive genetic condition. Deficiency…
BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency
ENERGY 3 study met 1 of 2 co-primary endpoints in children with ENPP1 deficiency Treatment with BMN 401 led to statistically significant increases in plasma inorganic pyrophosphate (PPi) concentration...
BioMarin reinstated with a Neutral at Goldman Sachs
Goldman Sachs reinstated coverage of BioMarin (BMRN) with a Neutral rating and $69 price target following the completion of the Amicus acquisition. While the shares are trading around the value…